erastin + trastuzumab

Erastin + trastuzumab is an experimental drug combination consisting of erastin, a small molecule inhibitor known to induce ferroptotic cancer cell death through inhibition of the cystine/glutamate antiporter, and trastuzumab, a humanized monoclonal antibody that targets the HER2/ErbB2 receptor, used primarily for HER2-positive cancers such as breast and gastric cancer. Erastin has been studied for its ability to sensitize certain tumor cells to ferroptosis, a non-apoptotic form of cell death. Trastuzumab binds to HER2, inhibiting downstream signaling pathways that drive cell proliferation. While trastuzumab is FDA-approved for HER2-positive breast and gastric cancers, the combination with erastin is investigational and currently not an approved therapy or standard clinical regimen. No human clinical trial data exist for the combination as of this date; any data are likely preclinical or hypothetical. The combination is postulated to have synergistic anti-tumor effects in HER2-overexpressing cancer cells due to dual targeting of ferroptosis pathways and HER2 inhibition.